1. [Biotherapy of malignant peritoneal effusions in ovarian carcinoma].
- Author
-
Titov KS, Gritsaĭ AN, Kiselevskiĭ MV, Sel'chuk VIu, Timova GV, Kuchmezov EKh, and Antonov AK
- Subjects
- Adult, Aged, Ascitic Fluid pathology, Carcinoma, Ovarian Epithelial, Female, Humans, Infusions, Parenteral, Middle Aged, Neoplasms, Glandular and Epithelial drug therapy, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Treatment Outcome, Antineoplastic Agents administration & dosage, Ascitic Fluid drug effects, Biological Therapy methods, Interleukin-2 administration & dosage, Killer Cells, Lymphokine-Activated, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms therapy
- Abstract
Malignant peritoneal effusions often arise in patients with ovarian carcinoma. They are a hazardous complication of cancer. Systematic intraperitoneal chemotherapy is not necessarily followed by long-term remission and may even induce untoward side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2/lymphokine-activated killers (LAK) biotherapy showed high efficacy in treatment of ovarian carcinoma patients suffering from peritoneal effusions. The objective effect was 80.1% and 82.6%, respectively. Our results suggest that intraperitoneal biotherapy may be extended to dealing with malignant peritoneal effusions in ovarian carcinoma.
- Published
- 2011